Rob Dillard

DocwireNews

Patients with refractory ulcerative colitis (UC) who are treated with Janus kinase inhibitors (JAKi) and withdrawal from therapy have significantly high rates of disease relapse and can benefit from resuming JAKi treatment, according to a study to be presented at Digestive Disease Week 2024, taking place May 18-21 in Washington, DC.In this multicenter, retrospective, cohort study, researchers analyzed outpatients with active UC at 3 institutions between September 2018 and April 2023. Patients in the population of interest had received current and/or previous treatment involving Tofacitinib (TOFA), Filgotinib (FIL), and Upadacitinib (UPA). A total of 86 cases (TOFA in 57, FIL in 16, and UPA in 13) were analyzed and classified into continuation and withdrawal groups. Cumulative relapse rates were assessed using Kaplan-Meier survival curves.According to the results, although patient-reported outcomes at 12 weeks were lower in the withdrawal group, the cumulative relapse rate in the withdrawal group was notably higher than in the continuation group. Encouragingly, the study found that the rate of clinical response after reintroduction of JAKi was 80.0%, and the rate of remission was 73.3%.&ldquo;Continuation of JAKi prevents clinical relapse, and resumption of JAKi may be effective even if the drug is withdrawn due to unavoidable circumstances,&rdquo; the researchers concluded.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Continuation of JAK Inhibitor Therapy Prevents Relapse in Patients With Ulcerative Colitis

DDW 2024

Patients with refractory UC who are treated with JAKi and withdrawal from therapy have significantly high rates of relapse.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe